About
BioSimulytics develops computational crystal structure prediction technology to predict and analyze the solid-form landscape of drug molecules early in drug development, helping pharmaceutical companies mitigate polymorph-related risks.
Explore BioSimulytics's full profile on Brouky
Funding rounds, investor list, and risk signals — unlock with a subscription.